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Neuregulin 1 and its receptor ErbB4 are conﬁrmed risk genes for schizophrenia, but the neuropatho-
logical alterations in NRG1-ErbB4 in schizophrenia are unclear. The present investigations therefore
focused on determining lamina speciﬁc (ErbB4-pan) and quantitative (pan, JMa, JMb, CYT1 and CYT2)
ErbB4 mRNA changes in the dorsolateral prefrontal cortex (DLPFC) in schizophrenia. We also determined
which neuronal proﬁles are ErbB4 mRNAþ in the human DLPFC and the relationship between ErbB4 and
interneuron marker mRNAs.
In situ hybridisation and quantitative PCR measurements were performed to determine changes in
ErbB4 splice variant mRNA levels in the DLPFC in schizophrenia (n ¼ 37) compared to control (n ¼ 37)
subjects. Cortical neurons expressing ErbB4-pan were labelled with silver grain clusters. Correlations
were performed between ErbB4 and interneuron mRNA levels.
ErbB4-pan mRNA was signiﬁcantly increased (layers I, II and V) in the DLPFC in schizophrenia. Silver
grain clusters for ErbB4-pan were detected predominantly over smallemedium neurons with low-no
expression in the larger, paler, more triangular neuronal proﬁles. ErbB4-JMa mRNA expression was
increased in schizophrenia. Somatostatin, neuropeptide Y and vasoactive intestinal peptide mRNAs
negatively correlated with ErbB4-JMa mRNA in people with schizophrenia.
Our ﬁndings demonstrate that ErbB4-pan laminar mRNA expression is elevated (layers I, II, V) in
schizophrenia. At the cellular level, ErbB4-pan mRNAþ signal was detected predominantly in
interneuron-like neurons. We provide evidence from this independent Australian postmortem cohort
that ErbB4-JMa expression is elevated in schizophrenia and is linked to deﬁcits in dendrite-targeting
somatostatin, neuropeptide Y and vasoactive intestinal peptide interneurons.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction 2004; Ghashghaei et al., 2006; López-Bendito et al., 2006; OkadaSchizophrenia is hypothesized to have genetic and neuro-
developmental origins (Harrison and Law, 2006; Norton et al.,
2006). Two critical neurodevelopmental genes that have been
linked to schizophrenia susceptibility are neuregulin 1 (NRG1) and
its receptor ErbB4 (Norton et al., 2006; Silberberg et al., 2006;
Stefansson, 2002). NRG1-mediated ErbB4 signalling is implicated
in a number of critical neurobiological processes, especially cortical
interneuron migration and interneuron differentiation (Anton
et al., 2004; del Pino et al., 2013; Fazzari et al., 2010; Flames et al.,Street, PO Box 1165, Rand-
99 1717, þ61 0420 967 902
ickert).
Ltd. Open access under CC BY-NC-SAand Corfas, 2004; Rio et al., 1997; Tamura et al., 2012). Abnormal
NRG1-ErbB4 signalling results in compromised development of the
brain circuitry involving GABA (gamma-aminobutyric acid)-
containing interneurons (Fazzari et al., 2010; Mei and Xiong,
2008; O’Tuathaigh et al., 2007; Stefansson, 2002). Determining
how alterations in ErbB4 expression in the prefrontal cortex are
linked to neuropathological changes in interneurons in schizo-
phrenia may facilitate our understanding of how susceptibility
genes operate at a molecular and cellular level.
ErbB4 is the major NRG1 receptor in the brain and is expressed
in developing and adult human brain (Bernstein et al., 2006; Fox
and Kornblum, 2005; Gerecke et al., 2001; Srinivasan et al., 1998;
Steiner et al., 1999). Four structurally and functionally distinct
ErbB4 splice variants have been identiﬁed that are differentially
spliced at exons encoding the extracellular juxtamembrane (JM) license.
Table 1
Summary of demographics for control and schizophrenia groups (mean  SD).
Control group
(n ¼ 37)
Schizophrenia
group (n ¼ 37)
Age (years) 51.1 (18e78) 51.3 (27e75)
Gender 7F, 30M 13F, 24M
Hemisphere 23R, 14L 17R, 20L
pH 6.66  0.30 6.61  0.30
Postmortem
interval
(hours)
24.80  10.97 28.46  13.77
RNA integrity
number
7.30  0.57 7.27  0.58
Subclass e Paranoid ¼ 16;
undifferentiated ¼ 7;
disorganised ¼ 5;
residual ¼ 2;
schizoaffective, depressive ¼ 4;
schizoaffective, bipolar type ¼ 3
Age of onset (years) e 23.7  0.10
Duration of illness
(years)
e 27.6  2.30
D. Joshi et al. / Journal of Psychiatric Research 53 (2014) 125e132126domain or the C-terminal cytoplasmic (CYT) tail (Corfas et al., 2004;
Mei and Xiong, 2008). The JM isoforms are distinguished by alter-
nate exons 16 (JMa) and 15 (JMb), with only the JMa isoform being
susceptible to proteolytic cleavage (Junttila et al., 2003, 2000). The
cytoplasmic isoforms differ by the presence of a 16 amino acid
insert (CYT1) or its absence (CYT2), respectively. Out of the two
known cytoplasmic isoforms, the ErbB4-CYT1 isoform is capable of
activating the phosphoinositide 3-kinase (PI3K) pathway (Junttila
et al., 2000) which is associated with regulating NRG1-induced
neuronal migration (Gambarotta et al., 2004) and in regulating
dendritic outgrowth (Higuchi et al., 2003). ErbB4-CYT2 activates
Shc-MAPK pathway and mediates proliferation (Kainulainen et al.,
2000). In schizophrenia, mRNA for the JMa and CYT1 splice variants
has previously been shown to be increased, but the full-length
“pan” transcript mRNA appears unchanged by quantitative real-
time polymerase chain reaction (qPCR) (Law et al., 2007;
Silberberg et al., 2006). The elevation in ErbB4 mRNAs in schizo-
phrenia has also not been found in the Stanley Array Collection
(https://www.stanleygenomics.org/stanley/geneDetail.jsp?gene_
id¼1476).
ErbB4 expression is required for the development of speciﬁc
inhibitory interneurons as well as the maturation and maintenance
of postnatal inhibitory connections in the mammalian cortex
(Fazzari et al., 2010). Among the different NRG1 isoforms, NRG1-
Type III is the most abundant isoform expressed in the brain e
predominantly in pyramidal neurons (Liu et al., 2011). NRG1-Type
III in pyramidal neurons promotes ErbB4-mediated inhibitory and
excitatory synapse formation (Fazzari et al., 2010; Ting et al., 2011).
Among the different known interneuron subtypes, somatostatin
positive (SSTþ) interneurons appear to be among the most affected
in people with schizophrenia in our cohort (Fung et al., 2010; Yang
et al., 2011) and others (Hashimoto et al., 2008a; Morris et al.,
2008). While it is known that ErbB4 protein is present in inhibi-
tory interneurons (Fazzari et al., 2010; Neddens et al., 2011; Woo
et al., 2007), it is still unclear as to how splice variant alterations
of ErbB4 mRNA may be distributed anatomically and/or how they
may relate to the state of various interneuron subtypes in people
with schizophrenia.
Further, conﬂicting data regarding ErbB4’s cellular localization
in the mammalian brain has led to major difﬁculty in verifying its
site of action. ErbB4 mRNA expression studies in rodent and
monkey cortex demonstrate an expression pattern consistent
with expression in interneurons (Fox and Kornblum, 2005;
Gerecke et al., 2001; Thompson et al., 2007), while the pres-
ence of ErbB4 in pyramidal neurons remains a matter of debate.
ErbB4 immunoreactivity has been observed in pyramidal neurons
in the rodent (Gerecke et al., 2001; Mechawar et al., 2007),
monkey (Thompson et al., 2007) and human cortex (Bernstein
et al., 2006). Recent studies have questioned these earlier ﬁnd-
ings and suggest that ErbB4 immunoreactivity is limited to
GABAergic interneurons (Neddens and Buonanno, 2011; Vullhorst
et al., 2009).
The present investigation therefore focused on determining (a)
lamina-speciﬁc changes in the expression of ErbB4-pan mRNA in
the DLPFC in schizophrenia by in situ hybridisation, (b) changes in
ErbB4 mRNA expression (CYT1, CYT2, JMa, JMb, pan) in a different
(Australian) postmortem cohort to the two previously reported
(Law et al., 2007; Silberberg et al., 2006), (c) cellular proﬁles (shape,
size) that positively express ErbB4-pan mRNA by labelling pre-
frontal cortical neurons with silver grains following in situ
hybridisation, and (d) the relationship between mRNA levels of
ErbB4 splice variants which are altered in schizophrenia and
interneuron marker mRNAs. We also determined the relative
expression of ErbB4 splice variant mRNAs with respect to the total
ErbB4 transcript mRNA population. As previous studies havereported increased ErbB4-CYT1 and ErbB4-JMa mRNA levels in the
prefrontal cortex in schizophrenia (Law et al., 2007; Silberberg
et al., 2006), we hypothesised that ErbB4-pan laminar expression
will be increased in schizophrenia in our study. We further
hypothesised that ErbB4 splice variant-speciﬁc alterations in the
DLPFC in schizophrenia would correlate with interneuron pathol-
ogy. This type of analysis, attempting to link risk gene expression
with known neuropathology, may provide better models of how
NRG1-mediated ErbB4 signalling could be linked to interneuron
dysfunction in schizophrenia.2. Materials and methods
2.1. Human postmortem brain tissue samples
Postmortem frozen tissues from 30 schizophrenia cases, 7
schizoaffective cases, and 37 well-matched control individuals
were provided by the New South Wales Tissue Resource Centre
(TRC cohort; Table 1). Characterisation of this Australian TRC
schizophrenia cohort has been described previously (Weickert
et al., 2010) [for details see Supplement 1].2.2. In situ hybridisation
Fourteen micro-metre (mm) thick frozen tissue sections (two/
case/probe) were thawed, ﬁxed, acetylated, delipidated, and
dehydrated as previously described (Whitﬁeld Jr. et al., 1990). Hy-
bridization buffer containing 35S-UTP labelled ErbB4-pan riboprobe
(5 ng/ml; corresponding to nucleotides 1605e2044, NM_005235)
was incubated on each section overnight at 55 C in humidiﬁed
chambers. As a control, 5 ng/ml of 35S-UTP labelled ErbB4-pan
sense riboprobe were applied to additional sections. Following
post-hybridisation RNase digestion, slides were washed and
exposed to BioMax MR (Kodak, Rochester, NY, USA) autoradio-
graphic ﬁlm for 4 weeks with carbon-14 standard slide (American
Radiolabeled Chemicals, St. Louis, MO, USA).
To determine mRNA localization at the cellular level for ErbB4-
pan containing transcripts, slides were dipped in autoradiographic
emulsion (Type-II NTB, Kodak, Rochester, NY, USA), dried and
developed after being in the dark for w12 weeks. Slides were
developed using D-19 developer (Kodak, Rochester, NY, USA) and
Nissl counterstained with thionin (for details see Supplement 1).
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qPCR analysis was conducted as reported previously (Weickert
et al., 2010). Total RNA was extracted from 300 mg gray matter
using Trizol (Invitrogen, Carlsbad, CA), and RNA quality was
determined using the Agilent Bioanalyzer 2100 (Agilent Technol-
ogies, Palo Alto, CA, USA). Samples had an average RNA integrity
number (RIN) of 7.3 (all samples had RIN  6.0). Complementary
DNA (cDNA) was synthesised using the Superscript II First-strand
Synthesis Kit (Invitrogen). Serial dilutions of pooled cDNA (from
all cases) created a standard curve, which was included on every
qPCR plate and sample expression was quantiﬁed by the relative
standard curve method using Sequence Detection Software (SDS;
Applied Biosystems, CA, USA). Control wells containing no cDNA
template did not display ampliﬁcation in any assay.
The ErbB4-JMa probe sequence published by Junttila et al. (2003)
was originally used for ErbB4-JMa mRNA detection, however this
probe failed to amplify efﬁciently in our hands. Further examination
of thepublishedprobe sequence identiﬁeda singlebasemismatch at
thepositionof the11thnucleotide (A rather thanC),whichmayhave
interferedwith the efﬁciency of the probe. Hencewe used the probe
sequence published by Silberberg et al. (2006) to detect ErbB4-JMa
isoform mRNA. Separate custom assays were designed for detec-
tion of ErbB4 splice variant mRNAs [JMa, JMb, CYT1, CYT2; see
Supplementary Table S1 for primer probe sequence details]. For
detection of JMb, CYT1 and CYT2, custom MGB probe sequences
were those from the Junttila study (Junttila et al., 2003). For ErbB4-
pan qPCR, an inventoried assay (Hs 00171783_m1; exon boundary
12e13 of transcript NM_005235) was ordered from Applied Bio-
systems (Foster City, CA, USA). Based on the relative expression of
each ErbB4 mRNA isoform relative to a standard curve, an appro-
priate cDNA dilution plate was used (1:30 for CYT2, JMb and pan;
1:12 for JMa; 1:6 for CYT1). A summary of probe locations for all
ErbB4 isoforms (qPCR and in situ) are given in Fig. 1.2.4. Statistical analysis
Tests for normality and homogeneity of variance were con-
ducted. For all measures performed, population outliers within a
group (schizophrenia or control subjects; 2SD from mean) wereFig. 1. Location of probes for ErbB4 isoforms produced by alternative splicing. The extracellu
respectively, are indicated with double headed arrows. Exon numbering used the nomenclat
exons are not known to be alternatively spliced and were not targeted by probes in the cu
domain (Cys-rich II; blue; 496e633aa), transmembrane domain (TM; grey; 652e675aa), n
(burgundy; 724e732aa), the catalytic protein kinase domain (PTKc; green; 718e985aa, span
respectively) and the PDZ-binding motif (purple; 1306e1308aa). Alternative splicing of exo
skips exon 26 and CYT1 includes exon 26. Inclusion of exon 16 (encoding 26 amino acids) res
acids) is utilised. For in situ hybridisation probes (red bar), the pan/full-length (extracellu
represented the last 16% of total probe length). For qPCR ampliﬁcation (blue arrows), JMa/JM
Probes speciﬁc for each isoform for qPCR are indicate with blue bars. (For interpretation of th
this article.)removed. For each measure performed, the number of excluded
outliers was between 1 and 3 individuals per group.
Repeated-measures analysis of variance was performed for
ErbB4-pan lamina-speciﬁc mRNA expression. As previous studies
(Law et al., 2007; Silberberg et al., 2006) have shown an increase in
ErbB4-JMa and ErbB4-CYT1 mRNAs in schizophrenia, we hypoth-
esised that JMa and/or CYT1 mRNA will be increased in our study.
We therefore, performed one-tailed t-test for ErbB4-JMa and
ErbB4-CYT1 mRNA levels determined by qPCR.
Two-way analysis of variance (ANOVA) was performed with
diagnosis and hemisphere, as between-groups independent vari-
ables, as well as for diagnosis and gender. Pearson’s correlations
were performed to determine whether ErbB4 mRNA expression
was related to demographic variables or interneuron marker
mRNAs [parvalbumin (PV), calbindin (CB), somatostatin (SST),
neuropeptide Y (NPY), calretinin (CR), vasoactive intestinal peptide
(VIP) and cholecystokinin (CCK); see Supplement 1 for details]. For
any measures having a signiﬁcant correlation with demographic
variables, analysis of covariance (ANCOVA) was used to test for
group differences. ANOVAs/ANCOVAswith p<.05 signiﬁcancewere
followed-up by Fisher’s least signiﬁcant difference post-hoc anal-
ysis to assess group differences.3. Results
3.1. Transcripts containing ErbB4-pan mRNA are increased (layers I,
II and V) in schizophrenia
ErbB4-pan mRNA levels were detected by our riboprobe in the
gray matter of control and schizophrenia subjects by in situ
hybridisation (Fig. 2AeC). From qualitative observation of the
autoradiographic ﬁlms, ErbB4-pan mRNA expression appeared to
be more robust in gray matter than in the white matter, somewhat
punctate and highest in the middle layers IVeV (in most sections)
and layer II (in some sections). The deep layer VI boundary and the
superﬁcial white matter boundary appeared diffuse (Fig. 2A and B).
ErbB4-pan sense control strand produced no hybridization signal
demonstrating antisense signal speciﬁcity (Supplementary Fig. S1).
Multiple cortical layers within the DLPFC gray matter showed
signiﬁcantly higher mean ErbB4-pan mRNA expression in schizo-
phrenia compared to control subjects (mean SD), including layer Ilar and intracellular components, encoded by amino acids (aa) 26e651 and 676e1308
ure of Junttila et al. (2003). In exon structure, only exons 9e28 are shown as the earlier
rrent study. The functional protein domains are annotated, with second cysteine-rich
uclear localisation signal (black; 676e684aa), the ﬁrst of three ATP binding domains
s exons 18e24), three PPxY motifs (orange; 1032e1035; 1053e1056 and 1298e1301aa
n 26 (encoding 16 amino acids) differentiates CYT1 from CYT2 isoforms, where CYT2
ults in JMa isoform, whereas in JMb, exon 16 is skipped and exon 15 (encoding 15 amino
lar) riboprobe spanned 438 bp including exons 12, 13, 14 and 16 (exon 16 sequence
b used the same ampliﬁcation primers, as was the case for CYT1/CYT2 ampliﬁcation.
e references to colour in this ﬁgure legend, the reader is referred to the web version of
Fig. 2. Representative in situ hybridization images showing ErbB4-pan messenger RNA
levels in human dorsolateral prefrontal cortex in (A) control (red ¼ layer I;
yellow ¼ layers II, III/IV, V, VI); and (B) schizophrenia subjects. (C) Laminar speciﬁc
ErbB4-pan mRNA levels (nCi/g) in the gray matter in control (gray) and schizophrenia
(black) subjects (*p < .05; **p < .01). Scale bar ¼ 3000 mm; error bars represent SEM.
(For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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(69.67  16.51 versus 60.98  16.81 nCi/g, p ¼ 0.006) and layer V
(85.33  17.46 versus 75.94  11.45 nCi/g, p ¼ 0.009; Fig. 2C).
Repeated-measures ANOVA showed a signiﬁcant interaction effect
of diagnosis and cortical layers on ErbB4-pan mRNA expression
(cortical layers IeVI; F ¼ 4.390, df ¼ 336, p ¼ 2.75  104).
3.2. qPCR: increased expression of ErbB4-JMa containing
transcripts in schizophrenia
Normalised ErbB4-JMamRNA level was signiﬁcantly increased in
peoplewith schizophrenia compared to control subjects (mean SD:
32.16  14.88 versus 26.31  12.37; t ¼ 1.74, df ¼ 65, p ¼ 0.04;
Fig. 3A). Normalised mRNA levels for ErbB4-JMb, ErbB4-CYT1 and
ErbB4-CYT2 were unchanged (all p > 0.05; Fig. 3BeD) with a trend
towards ErbB4-pan mRNA reduction (p ¼ 0.06; Fig. 3E) in schizo-
phrenia compared to control subjects. Evaluation of the relativeexpression of each ErbB4 mRNA isoform revealed that CYT2-
containing transcripts are the principle isoform in the DLPFC, and
are w4.5 fold increased compared to CYT1-containing transcripts
(82%vs18%respectively; Fig. 3F). Transcripts containing JMbarew1.6
times increased compared to JMa-containing transcripts (62% vs 38%
respectively; Fig. 3F). For correlations of mRNA with demographic
measures see Supplementary Table S2.
3.3. Relationship between ErbB4 splice variant mRNA levels and
interneuron marker mRNAs
Next, we examined the relationship between ErbB4 transcript
altered in schizophrenia in our sample (ErbB4-JMa) and inter-
neuron marker mRNAs (PV, CB, SST, NPY, CR, VIP, CCK; see Table 2)
which we previously quantiﬁed (Fung et al., 2010). ErbB4-JMa
mRNA level negatively correlated with SST (r ¼ 0.508,
p ¼ 0.002), NPY (r ¼ 0.563, p ¼ 5.31 104) and VIP (r ¼ 0.399,
p ¼ 0.018) mRNA levels in people with schizophrenia. In controls,
ErbB4-JMa negatively correlated with CCK mRNA expression
(r ¼ 0.455, p ¼ 0.007).
3.4. Cellular localisation of ErbB4 mRNA expression in the DLPFC
In all cases examined qualitatively (37 control, 37 schizo-
phrenia), ErbB4-pan mRNAþ silver grain clusters were detected
over many, but not all, smallemedium sized neurons in the cortical
gray matter (Fig. 4A e red arrow-heads). The mediumelarge more
triangular-shaped cell proﬁles expressed low to no ErbB4-pan
mRNAþ silver grain clusters (Fig. 4A and B e green arrow-heads).
The majority of glial cells (Fig. 4 A and B; intense blue small cir-
cular shapes) did not show any ErbB4-pan mRNAþ signal above
background levels. ErbB4-pan mRNAþ signal was also detected
over neuronal-like proﬁles in the superﬁcial white matter close to
the gray matter (data not shown).
4. Discussion
The current study, for the ﬁrst time, provides information on
lamina-speciﬁc changes in ErbB4-pan containing mRNA transcript
expression in schizophrenia. Lamina-speciﬁc increases in ErbB4-
pan mRNA expression in schizophrenia were consistent with our
original hypothesis. We also demonstrate that the ErbB4-JMa splice
variant is increased in people with schizophrenia compared to
controls. In schizophrenia, we ﬁnd that elevated level of ErbB4-JMa
splice variant is linked to decreases in dendrite-targeting inter-
neuron mRNAs such as those containing SST, NPY and VIP mRNAs.
4.1. qPCR versus in situ ﬁndings: similarities and differences
Two previous studies have speciﬁcally examined ErbB4 mRNA
alterations in schizophrenia using entirely independent postmor-
tem cohorts (Law et al., 2007; Silberberg et al., 2006). Both these
studies reported an increase in ErbB4-CYT1 and ErbB4-JMa splice
variant mRNA in schizophrenia patients compared to control sub-
jects but no change in the other ErbB4 splice variants (CYT2, JMb).
Surprisingly, no change in total ErbB4 expression measured by a
pan (encoding “extracellular” exonic region) was observed (Law
et al., 2007), despite signiﬁcant increases in two ErbB4 isoforms.
Our quantitative relative measurement for different ErbB4 isoforms
to the total ErbB4 mRNA population may help to explain this
apparent contradiction. Both JMa- and CYT1-containing transcripts
represent a smaller proportion of the total ErbB4 mRNA population
and hence elevation in these two splice variants may not be
apparent in the ErbB4-pan mRNA levels. This further supports our
in situ hybridisation approach demonstrating that more
Fig. 3. Normalised ErbB4 splice variant mRNA levels in the human dorsolateral prefrontal cortex (A) JMa, (B) JMb, (C) CYT1, (D) CYT2, and (E) pan. Error bars represent SEM. *
represents p < .05. (F) Expression of different mRNA splice variants relative to total ErbB4 mRNA.
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found in schizophrenia.
We were able to detect lamina-speciﬁc mRNA increases in
ErbB4-pan (layers I, II, V) in schizophrenia patients compared to
control subjects. Differences observed with in situ hybridisation
(lamina-speciﬁc) may possibly have been diluted when using a
homogenate-based approach (qPCR). In addition, the ErbB4-pan
riboprobe used in our study binds to the region encoding the
ErbB4-cystine-rich domain spanning exons 12e16 but excluding
JMb exon 15, whereas the ErbB4-pan qPCR assay used was speciﬁc
for the exon-boundary 11e12 [using exon numberingnomenclature described in (Junttila et al., 2003)]. It is possible that
our ErbB4-pan riboprobe may be more efﬁcient in detecting JMa-
containing isoforms relative to JMb-containing isoforms, whereas
the ErbB4-pan qPCR assay probe would detect JMa and JMb equally
effectively.
While PCR based methods are generally considered the “gold-
standard” for quantifying mRNA expression, in situ hybridisation
has previously been extensively used by ourselves and others to
quantify mRNA expression in the cortex (Beneyto et al., 2011, 2012;
Joshi et al., 2012; Morris et al., 2008, 2009; Siegel et al., 2013). One
could argue that in situ hybridisation may have some advantages in
Table 2
Correlation between ErbB4-JMa transcripts and inhibitory interneuron marker
mRNAs in the DLPFC (*p < 0.05, **p < 0.01, ***p < 0.001).
ErbB4-JMa Control Schizophrenia
r p r p
Parvalbumin 0.238 0.197 0.297 0.087
Calbindin 0.058 0.740 0.255 0.139
Somatostatin 0.338 0.051 L0.508 0.002**
Neuropeptide Y 0.191 0.271 L0.563 5.31 3 10L4***
Calretinin 0.102 0.562 0.195 0.269
Vasoactive intestinal peptide 0.057 0.753 L0.399 0.018*
Cholecystokinin L0.455 0.007** 0.170 0.329
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structure as the cerebral cortex. The reliability and quantitative
capability of in situ hybridisation in the cortex has recently been
directly compared with qPCR data from the same individuals
(Siegel et al., 2013), where strong correlations (r ¼ 0.72) were
observed between data generated by both methods.
Reduced cortical thickness is known in people with schizo-
phrenia (Schultz et al., 2010) which may be expected to cause an
increase in density of interneurons which are ErbB4-extracellular
mRNAþ, and an increase in signal from ﬁlm-based analysis as
compared to homogenate based analysis. Interestingly, in the hu-
man DLPFC, SST neuron density is highest in layers IIesuperﬁcial III
and layer V (Morris et al., 2008), and in schizophrenia, SST mRNA is
particularly reduced in layers II, III and V (Hashimoto et al., 2008a,
2008b; Morris et al., 2008). In people with schizophrenia in our
cohort, we ﬁnd that increased ErbB4-JMa splice variant is linked to
a reduction in SST mRNA. Our ﬁndings suggest that an increase in
transcripts encoding the cleavable extracellular region of ErbB4
(layers I, II, V) may relate to reduction in inhibitory neuropeptide
mRNA in the SST/NPY-containing (predominantly Martinotti cells)
interneuron subtypes in schizophrenia. Further work will be
required to determine if the reduction in SST and NPY mRNA is due
to a change in the number of SSTþ/NPYþ neurons or reduction in
gene expression per neuron.4.2. ErbB4-CYT1 mRNA expression in the DLPFC
Contrary to the original hypothesis and previous reports (Law
et al., 2007; Silberberg et al., 2006) demonstrating elevated
ErbB4-CYT1 mRNA expression, we found no change in ErbB4-CYT1
mRNA expression in people with schizophrenia compared to con-
trol subjects. It is unclear if this inconsistency may be due to theFig. 4. Representative images from the human dorsolateral prefrontal cortex showing: ErbB
[B]. Red arrow-heads ¼ small-medium ErbB4-pan mRNAþ neuronal proﬁles; green arrow-he
Scale bar ¼ 20 mm. mRNA, messenger RNA. (For interpretation of the references to colourdifferences in the cohort population where the previous cohort
(Law et al., 2007) had many African-American cases, whilst the
Australian postmortem cohort in the present study consists pri-
marily of Caucasian individuals. To date, ErbB4-CYT1 mRNA levels
have been speciﬁcally examined in three different cohorts
(including the current one). Two of these reports (Law et al., 2007;
Silberberg et al., 2006) have shown an elevation in ErbB4-CYT1
mRNA whereas our current study ﬁnds no change. A recent report
proposes ErbB4-CYT1 linked p110d (phosphoinositide 3-kinase
subunit) as a potential therapeutic target for the treatment of
psychiatric disorders (Law et al., 2012). Taking current ﬁndings and
the number of studies published into consideration, we suggest
further studies are warranted to conﬁrm or refute elevated ErbB4-
CYT1 mediated NRG1-ErbB4 signalling in schizophrenia.4.3. qPCR correlations: ErbB4 splice variant mRNA and interneuron
markers
We found an elevation in ErbB4-JMa mRNA in people with
schizophrenia, we therefore performed correlations between ErbB4-
JMa mRNA expression and inhibitory interneuron marker mRNAs.
ErbB4-JManegativelycorrelatedwith inhibitoryneuropeptidemRNAs
(SST, NPY and VIP) in people with schizophrenia suggesting elevated
levelsof ErbB4-JMasplicevariantmRNAmaypotentiallybenegatively
inﬂuencing bitufted/dendrite-targeting neuropeptide (SST, NPY and
VIP)mRNAs. To our knowledge, this is the ﬁrst evidence linking ErbB4
splicevariant (ErbB4-JMa)mRNAwith reduced inhibitory interneuron
mRNAs in people with schizophrenia. In controls, ErbB4-JMa mRNA
expression inversely correlated with CCK (neuropeptide) mRNA sug-
gesting that CCK may have a distinct link to ErbB4-JMa mRNA
expression in the healthy DLPFC. Importantly, our correlations
demonstrate that among all the interneuron mRNAs, neuropeptide
mRNAs are especially linked with ErbB4-JMa mRNA expression.
ErbB4 is known to be predominantly expressed in PV in-
terneurons (Fazzari et al., 2010) but also in SSTþ interneurons
(Fazzari et al., 2010; Neddens et al., 2011;Woo et al., 2007).Most SST
immunoreactive cells co-express calbindin (w86%; Gonchar and
Burkhalter, 1997; Markram et al., 2004) with an overlapping
laminarcortical expression (DeFelipeet al.,1989;Morris et al., 2008).
Typically, PV interneurons are largelypresent in cortical layers IIIeIV
(Beasley and Reynolds,1997), where they contact the pyramidal cell
soma (basket cells) or the axon initial segment (chandelier cells).
Surprisingly, our analysis did not reveal any strong relationship
between ErbB4-JMa and PV mRNA. However, our correlations
identiﬁed SST and NPY interneuron mRNAs to be reduced with
elevated ErbB4-JMa splice variant mRNA in schizophrenia. The4-pan mRNAþ cells in the gray matter (layers IVeV) at 20 [A] and 40 magniﬁcation
ads ¼medium-large neuronal proﬁles showing low to no ErbB4-pan mRNA expression.
in this ﬁgure legend, the reader is referred to the web version of this article.)
D. Joshi et al. / Journal of Psychiatric Research 53 (2014) 125e132 131laminar ErbB4-pan mRNA increase (layers I, II, V) in the present
study is speciﬁc to layers that are not PV interneuron enriched (deep
layer III, layer IV) (BeasleyandReynolds,1997; Reynolds andBeasley,
2001; Reynolds et al., 2002). This suggests that in our cohort, the
interneuron subpopulation most impacted by altered ErbB4-JMa
signalling in schizophrenia may most likely be the SST/NPY-
containing Martinotti or bitufted interneuron.
One of the most consistent ﬁndings emanating from the current
and previous studies is the elevated ErbB4-JMa splicing isoform in
the human DLPFC in people with schizophrenia. ErbB4-JMa en-
codes extracellular ecto-ErbB4 protein. It is possible that elevated
levels of cleaved ecto-ErbB4 may neutralise the membrane-bound
CRD-NRG1 (encoded by NRG1-Type III synthesized by pyramidal
neurons) resulting in reduced cross-talk between NRG1 and ErbB4.
Importantly, NRG1-ErbB4 signalling has been shown to be impor-
tant for the development of inhibitory circuits, and a reduction in
NRG1-ErbB4 cross-talk does result in reducedmolecular markers of
inhibitory synapses (Fazzari et al., 2010; Krivosheya et al., 2008).
Alternatively, elevated levels of cleaved ecto-ErbB4 may result in
increased NRG1 backward-signalling, and in turn, altered gene
expression in schizophrenia. This observation is consistent with our
previous ﬁndings linking the schizophrenia-associated HAPICE risk
haplotype (Stefansson, 2002) with increased NRG1-Type III mRNA
expression (Weickert et al., 2012), and our earlier observations of
increased cytoplasmic NRG1-ICD in schizophrenia (Chong et al.,
2008). However, it is not known if the increase in mRNA for the
cleavable isoform of ErbB4-JMa actually results in more cleaved
ecto-ErbB4 at the protein level. Thus, future work could speciﬁcally
address these important questions.4.4. ErbB4 cellular localization in the DLPFC
Cellular localization of ErbB4 in the neurons has been amatter of
debate with inconsistent ﬁndings at the protein level. While some
studies report ErbB4 protein detection in interneurons and pyra-
midal cells (Bernstein et al., 2006; Thompson et al., 2007), more
recent reports provide evidence suggesting ErbB4 immuno-
localisation is correctly identiﬁed in interneurons only (Neddens
et al., 2011; Vullhorst et al., 2009). In the present study, tran-
scripts containing ErbB4-pan mRNA were detected predominantly
in smallemedium sized round cells whereas the mediumelarge
triangular cell bodies had very low to no ErbB4-pan mRNAþ silver
grains. Consistent with ErbB4 protein studies which suggest that
ErbB4 protein is expressed predominantly in PV interneurons,
ErbB4 mRNAþ signal was detected in most but not all smalleme-
dium sized cell bodies in the DLPFC. We provide ﬁrst evidence
demonstrating ErbB4-pan mRNAþ signal in the human DLPFC,
consistent with studies showing ErbB4 protein expression in the
interneurons (Neddens et al., 2011; Vullhorst et al., 2009). It still
remains unclear if the ErbB4-cytoplasmic splice variants may have
any contribution to the ErbB4 immunopositive signal detected in
pyramidal neurons (Bernstein et al., 2006; Thompson et al., 2007)
which may not have been detected with the “extracellular”/pan-
ErbB4 riboprobe used in the present study. Future studies may be
able to address any such possibilities.4.5. Limitations
Our study focused on laminar ErbB4 expression changes at the
mRNA level and did not attempt to examine laminar changes at the
protein level. This decision was partly due to the less quantitative
nature of immunohistochemistry, and partly due to the lack of
availability of appropriate antibodies truly representing pan-ErbB4.4.6. Conclusion
To conclude, the present ﬁndings demonstrate that ErbB4-pan
mRNA levels are elevated in layers I, II and V in schizophrenia. It
is possible that elevated levels of ErbB4-JMa may contribute to the
observed laminar elevation in ErbB4-pan mRNA levels in people
with schizophrenia. Importantly, we demonstrate that elevated
levels of ErbB4-JMa are linked to the viability of dendrite-targeting
neuropeptide-expressing interneurons (SST, NPY, VIP). While the
present ﬁndings provide a new insight into the altered NRG1-ErbB4
signalling in people with schizophrenia, it also raises a number of
important questions, such as (a) how could elevated ErbB4-JMa
splice variants contribute causally to the interneuron pathology in
schizophrenia, and (b) how could ErbB4-JMa mRNA levels be
reduced and would this lead to changes in interneuron mRNAs and
to possible beneﬁt for people with schizophrenia? Further studies
are warranted to answer these critical questions, and in turn, clarify
the existing ambiguity pertaining to NRG1-ErbB4 signalling espe-
cially in context of the need for more precise ErbB4 cellular local-
isation and examination of ErbB4 protein processing in human
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